Based on the latest evidence, which is better for acute kidney injury: intermittent hemodialysis (IHD) or continuous renal replacement therapy (CRRT)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 23, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Intermittent Hemodialysis vs CRRT in AKI: Which is Better?

Neither modality demonstrates superior mortality outcomes in acute kidney injury, and both should be used as complementary therapies based on clinical context 1, 2. However, for hemodynamically unstable patients, CRRT is preferred over standard intermittent hemodialysis 2.

Clinical Decision Algorithm

Use CRRT preferentially when:

  • Hemodynamic instability (hypotension, requiring vasopressors) 2
  • Acute brain injury with increased intracranial pressure or generalized cerebral edema 2
  • Need for slower, more controlled solute shifts to avoid rapid osmotic changes 2

Use IHD or SLED when:

  • Hemodynamically stable patients
  • CRRT unavailable or limited resources
  • Need for more efficient solute clearance per session 3
  • Centers with established SLED protocols (can match CRRT hemodynamic stability) 1, 2

Evidence Analysis

Mortality: No Clear Winner

The guideline evidence from KDIGO/KDOQI (2013) establishes that no survival benefit exists for either modality 1, 2. This is reinforced by recent research:

  • A 2022 secondary analysis of AKIKI and IDEAL-ICU trials (543 patients) found CRRT as first modality showed no survival benefit and potentially worse outcomes in less severely ill patients (SOFA 3-10), with weighted HR 1.82 favoring IHD 4
  • A 2020 meta-analysis confirmed no significant differences in renal recovery, in-hospital mortality, or ICU mortality between CRRT and IHD 5
  • A 2022 Turkish study (120 patients) showed no mortality difference (66.7% overall mortality in both groups) 3

Hemodynamic Tolerance: CRRT Advantage

CRRT provides better hemodynamic stability with less pronounced drops in mean arterial pressure compared to IHD 6, 3. A 2025 Chinese study (256 patients) demonstrated:

  • Smaller MAP decrease with CRRT
  • Lower complication rates with CRRT
  • More pronounced heart rate elevation with IHD 6

However, the 2022 Turkish study found greater MAP reduction with IHD (statistically significant, p<0.001) 3, supporting guideline recommendations for CRRT in unstable patients.

Metabolic Control: IHD More Efficient Per Session

IHD achieves greater improvement in laboratory parameters per treatment session 3. The Turkish study showed statistically greater improvements in urea, creatinine, electrolytes, and acid-base parameters with IHD compared to CRRT (p<0.001) 3. However, this doesn't translate to mortality benefit.

Renal Recovery: Conflicting Data

  • A 2026 Polish study (128 patients) found IHD associated with higher rates of long-term dialysis dependence after hospital discharge (p=0.001) 7
  • The 2022 AKIKI/IDEAL-ICU analysis showed no difference in kidney recovery between modalities 4
  • The 2020 meta-analysis found no significant difference in renal recovery between CRRT and SLED 5

Critical Nuances and Pitfalls

SLED as Middle Ground

Sustained low-efficiency dialysis (SLED) represents a viable alternative that combines advantages of both modalities 1, 2. The Canadian guideline commentary notes controversy about whether SLED should be considered inferior to CRRT, as some centers use it interchangeably with comparable hemodynamic stability 1. The KDOQI commentary explicitly states SLED can be safely used in hemodynamically unstable adult patients 2.

Severity-Dependent Outcomes

The 2022 AKIKI/IDEAL-ICU analysis revealed a critical finding: in less severely ill patients (SOFA 3-10), IHD may actually be superior to CRRT (weighted HR 1.82, p<0.01) 4. This challenges the blanket recommendation for CRRT and suggests modality choice should consider illness severity.

Resource and Expertise Considerations

Guidelines emphasize that modality selection should be dictated by local availability and expertise 1, 2. CRRT is more expensive with no proven survival benefit 1, making IHD or SLED reasonable first-line options in stable patients or resource-limited settings.

Anticoagulation Implications

Regional citrate anticoagulation is preferred for CRRT 2, but the KDOQI commentary notes FDA-approved citrate solutions are lacking in the US 2, which may influence practical implementation.

Practical Recommendations

Start with patient hemodynamics as your primary decision point:

  1. Unstable (vasopressors, MAP <65) → CRRT or SLED
  2. Stable → IHD acceptable and potentially preferable
  3. Brain injury/elevated ICP → CRRT (slower solute shifts)
  4. Moderate illness (SOFA 3-10) → Consider IHD based on recent evidence 4

Deliver adequate dosing regardless of modality:

  • CRRT: 20-25 mL/kg/h effluent volume 2
  • IHD: Kt/V of 3.9 per week 2

Monitor for modality-specific complications:

  • IHD: Greater hemodynamic fluctuations, dialysis disequilibrium
  • CRRT: Citrate accumulation (especially with liver failure), higher cost, immobilization

The evidence does not support dogmatic adherence to one modality. Use them as complementary therapies, switching based on evolving clinical circumstances 1, 2.

References

Related Questions

What is the International Continuous Renal Replacement Therapy in Acute Kidney Injury (ICRAKI) trial?
In acute kidney injury, which renal replacement therapy modality—continuous renal replacement therapy or intermittent hemodialysis—is preferred based on the patient’s hemodynamic status?
What are the causes of acute kidney injury?
What is the recommended management algorithm for acute kidney injury?
What is the appropriate management of acute kidney injury secondary to blood loss in an adult patient?
If I was diagnosed with Lyme disease last year, is there any benefit to taking doxycycline as post‑exposure prophylaxis this year?
Is doxycycline safe to use during the third trimester of pregnancy?
How should proton‑pump inhibitors be prescribed and monitored in a patient with chronic kidney disease, and what are alternative acid‑suppression options?
Is it safe to prescribe selegiline 2.5 mg once daily together with betahistine 48 mg once daily?
Why would vortioxetine be preferred over other antidepressants for a patient who uses cannabis (THC) and experiences irritability?
What is the therapeutic dose of mirtazapine for anxiety?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.